GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake

Inclusion criteria: * Caucasian men * Age between 18 and 70 years * Body mass index (BMI) between 25 and 40 kg/m2 * Type 2 diabetes (diagnosed according to the criteria of the World Health Organization) with HbA1c \<69 mM (\<8.5 %) * In stable treatment for ≥3 months with metformin ≥1 g and a GLP-1 receptor agonist. * Informed consent Exclusion criteria * Anaemia (haemoglobin outside normal range) * Any current or prior gastrointestinal disease that may interfere with the endpoint variables * Liver disease (alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) \> 2 times normal values) or history of hepatobiliary disorder. * Nephropathy (serum creatinine above normal range and/or albuminuria). * Anorexia, bulimia or binge eating disorder * Allergy or intolerance to ingredients included in the standardised meals * Tobacco smoking * Treatment with other glucose lowering drugs than GLP-1 receptor agonists and metformin. * Any regular drug treatment (besides metformin and GLP-1 receptor agonists) that cannot be discontinued for a minimum of 12 hours * Any physical or psychological condition that the investigator feels would interfere with trial participation